Quoin Pharmaceuticals, Ltd. (QNRX) Stock Forecast
QNRX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.83 / 5 from 6 analysts
- Price target
- $20.71 average of analyst targets
- Upside to target
- +431.1% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-1.88
- 52-week range
- $3.25 – $22.30
QNRX analyst ratings
6 analystsNumber of analysts at each rating.
QNRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
QNRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.76 | −$2.05 | −$1.47 | −$6.70 | +73.7% | 2 |
| Current fiscal year (2026) | −$7.17 | −$7.89 | −$6.45 | −$14.80 | +69.0% | 2 |
| Next fiscal year (2027) | −$3.19 | −$4.45 | −$1.92 | −$7.17 | +55.6% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
QNRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 6 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 6 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 5 |
QNRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
QNRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.69 | −$1.69 | −$1.76 | −$1.76 | −$1.76 | +4.5% | 0 up · 1 down |
| Current fiscal year (2026) | −$6.88 | −$6.88 | −$7.17 | −$7.17 | −$7.17 | +4.2% | 1 up · 1 down |
| Next fiscal year (2027) | −$2.91 | −$2.91 | −$3.19 | −$3.19 | −$3.19 | +9.5% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
QNRX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; QNRX beat in 7 of 12.
What analysts expect from QNRX
6 analysts cover Quoin Pharmaceuticals; their consensus rating is strong buy (4.83 on a 1–5 scale, where 5 is a strong buy). The average price target is $20.71, 431.1% above the latest close of $3.90. Analysts expect earnings of −$7.17 per share for 2026, +69.0% from a year earlier. For 2027 the average estimate is −$3.19 per share. Quoin Pharmaceuticals beat the EPS estimate in 7 of the last 12 quarters.
Related: QNRX income statement, QNRX key metrics, QNRX chart. See the QNRX stock overview for the latest quote and news.
QNRX forecast FAQ
What is Quoin Pharmaceuticals's price target?
The average analyst price target for Quoin Pharmaceuticals is $20.71, 431.1% above the latest close of $3.90.
Is Quoin Pharmaceuticals a buy, hold or sell?
Of 6 analysts covering Quoin Pharmaceuticals, 5 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Quoin Pharmaceuticals's EPS forecast?
Analysts forecast −$7.17 per share for 2026 (range −$7.89 to −$6.45); for 2027 the estimate is −$3.19.
When does Quoin Pharmaceuticals report earnings?
Quoin Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 5, 2026; the EPS estimate is $-1.88.
Does Quoin Pharmaceuticals usually beat earnings estimates?
Quoin Pharmaceuticals reported EPS at or above the analyst estimate in 7 of the last 12 quarters.